Tercica Inc. (TRCA)

[coinstarz]

C.E Unterberg initates TRCA with an Underperform and a $2-3 tgt saying they expect continued clarity into the progress of Increlex's launch, they remain cautious on its future prospects. They say their cautiousness stems from Tercica's inferior safety profile when compared to that of its main competitor, Insmed's IPLEX. The firm notes Increlex had a 68% incidence of adverse events in its pivotal clinical trial compared to 48% for IPLEX

http://www.briefing.com/Investor/Public/MarketAnalysis/Calendars/UpgradesDowngra desAlphaSort.htm